Fig. 1From: Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registryResponse rates at different time intervals. The two types of analyses conducted in patients who discontinued treatment are shown: BCF: baseline carried forward, LOCF: last observation carried forwardBack to article page